Author

J.-Y. Song

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

A. Schepers· 1 shared A. Shahrabi· 1 shared A. Velds· 1 shared B. de Bruijn· 1 shared C. Lieftink· 1 shared C. U. Blank· 1 shared D. J. Adams· 1 shared D. S. Peeper· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Schepers

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity

Z. Pogacar, J. L. Johnson, L. Krenning, G. De Conti, C. Lieftink, A. Velds, L. Wardak, F. Jochems, K. Groot, A. Schepers, L. Wang, J.-Y. Song, M. van de Ven, O. van Tellingen, R. H. Medema, , R. Leite de Oliveira

The paper identifies that combining indisulam with palbociclib enhances senescence in cancer cells by inhibiting CDK2 kinase activity.

bioRxiv · Oct 18, 2021Cancer Biology

PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENT

O. Krijgsman, K. Kemper, J. Boshuizen, D. W. Vredevoogd, E. A. Rozeman, S. Ibanez Molero, B. de Bruijn, P. Cornelissen-Steijger, A. Shahrabi, M. Del Castillo Velasco-Herrera, J.-Y. Song, M. A. Ligtenberg, R. J. C. Kluin, T. Kuilman, P. Ross-MacDonald, , D. S. Peeper

This paper develops two genetic signatures, InTumor and ExTumor, to predict immune checkpoint blockade response in melanoma patients, enabling stratification for monotherapy or combination therapy.

bioRxiv · Jul 14, 2020 · PreprintCancer Biology

Histone methyltransferase DOT1L controls state-specific identity during B cell differentiation

M. A. Aslam, M. F. Alemdehy, E. M. Kwesi-Maliepaard, M. Caganova, I. N. Pardieck, T. van den Brand, F. I. Muhaimi, T. van Welsem, I. de Rink, J.-Y. Song, E. de Wit, R. Arens, K. Rajewsky, H. Jacobs, F. van Leeuwen

This study identifies DOT1L as a key regulator of B cell differentiation by controlling epigenetic programs that maintain B cell naivety and support germinal center formation.

bioRxiv · Mar 25, 2020Immunology